Are you Dr. Farajallah?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 37 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
777 Scudders Mill Rd
Ms P11-26
Plainsboro, NJ 08536Phone+1 609-897-3124Fax+1 609-897-6068
Summary
- Dr. Awny Farajallah, MD is an infectious disease specialist in Plainsboro, New Jersey. He is currently licensed to practice medicine in New Jersey, Pennsylvania, and Arkansas.
Education & Training
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1995 - 1998
Cairo University School of MedicineClass of 1991
Certifications & Licensure
NJ State Medical License 2002 - 2025
AR State Medical License 1997 - 2021
PA State Medical License 2004 - 2008
Awards, Honors, & Recognition
- Fellow (FACP) American College of Physicians, 2006
Publications & Presentations
PubMed
- 8 citationsChanges in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patient...Graeme J. Moyle, Helene Hardy, Awny Farajallah, St John McGrath, Stephen Kaplita
Journal of Acquired Immune Deficiency Syndromes. 2015-01-01 - 18 citationsPharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE StudyLi Zhu, Shanmei Liao, Michael Child, Jenny Zhang, Anna Persson
The Journal of Antimicrobial Chemotherapy. 2012-02-01 - 147 citationsAbacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final ResultsPaul E. Sax, Camlin Tierney, Ann C. Collier, Eric S. Daar, Katie R. Mollan
The Journal of Infectious Diseases. 2011-10-15
Press Mentions
Phase 3 Trial of ICLUSIG® (Ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the USNovember 17th, 2022- Chutes & Ladders—AstraZeneca Internally Promotes Galbraith to Helm Cancer R&DJuly 2nd, 2021
- BioSpace Movers & Shakers, July 2July 1st, 2021
- Join now to see all
Professional Memberships
- Fellow
